Observational studyRheumatology international2025
Serum ferritin as a specific biomarker of anti-MDA5-interstitial lung disease: a multicenter, case-control study in observational and validation datasets.
Observational study in Rheumatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A transfer learning-based multimodal model for early prediction of 90-day respiratory failure in dermatomyositis-associated interstitial lung disease.Frontiers in immunology · 2026Article
- Correlation of a combined serum biomarker panel with the composite physiologic index in connective tissue disease-associated interstitial lung disease.Frontiers in physiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSerum ferritin has been proposed as biomarker of interstitial lung disease (ILD) in anti-MDA5 dermatomyositis (DM). Nevertheless, no data exist for serum ferritin in other idiopathic inflammatory myopathies (IIM)-ILD nor in IIM without ILD. Aim of this case-control study was to assess whether serum ferritin may be considered a specific and sensitive biomarker for IIM-ILD, as well as to assess whether it correlates with clinical and immunological findings. PATIENTS AND
methodsAll patients affected by IIM and followed at Siena (Italy), Palermo (Italy), Bari (Italy) and Lucknow, (India) IIM referral centers were retrospectively included. They had diagnosis of DM and ASS, with and without ILD. Myositis specific or myositis associated antibodies were tested through line immunoassay (Euroimmune, Lubeck, Germany). Serum ferritin concentrations at the first assessment (T0) were detected by ChemiLuminescent Enzyme Immunoassay technology.
resultsA total of 139 IIM patients (study cohort n = 51 and validation cohort n = 88; mean age and standard deviation 44.3 ± 17.75) were included. The most common subtype was DM (n = 70, 50.3%), followed by ASS (n = 50, 35.9%). The three most common MSAs were MDA5 (n = 25, 18%), Jo1 (n = 25, 18%) and Mi2 (n = 10, 7%). ILD was assessed in 69 subjects. Ferritin values were higher in DM-MDA5 than DM-non-MDA5 (p = 0.0073) and ASS (p = 0.0006). All 69 patients affected by ILD were subsequently divided showing statistically significant difference for ferritin (p = 0.0013).
conclusionOur study included a huge number of patients from multicenter datasets, comprising patients of different ethnicities. Ferritin values lower than 303.5 ng/ml evaluated for the first time in a patient with suspected IIM and ILD, waiting for autoimmunity tests, allowed to exclude MDA5-DM. The strength of our findings was corroborated by binomial logistic regression, which proved the independence of ferritin from CPK and CRP to identify DM-MDA5-ILD. Such evidence allows to exclude that ferritin values are influenced by systemic inflammation.
Indexed as
Identifiers
40663209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.